Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland

Johanna J. Zirpel1,2,3 · Isabel B. Pfister1,2,3 · Christin Gerhardt1,2,3 · Justus G. Garweg1,2,3,4

Abstract
Objective To assess the long-term visual outcomes in eyes with symptomatic diabetic macular oedema (DME) under intravitreal treatment (IVT) in a clinical routine setting.
Methods Patients with newly diagnosed DME were included in this retrospective study if they had received at least three IVTs and a follow-up period ≥ 2 years. Due to altered treatment patterns since the approval of ranibizumab for DME in 2012, patients were subdivided according to their first IVT before 2013 (group 1) or thereafter (group 2). The primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time.
Results Of 217 eyes (191 patients) with DME, 151 eyes (117 patients) fulfilled the inclusion criteria (63 eyes in the first period, 88 in the second period). Mean follow-up time was 7.9 ± 3.1 (group 1) and 4.1 ± 1.4 years (group 2; p < 0.001). Visual gains were similar in the first year (group 1: +5.3 ± 15.5, group 2: +7.3 ± 12.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; p = 0.44), but not thereafter (after 2 years in group 1: +4.4 ± 15.0, group 2: +8.3 ± 13.0 ETDRS letters; p = 0.038). During the first year, group 1 patients received less clinical examinations (group 1: 6.6 ± 3.3, group 2: 7.5 ± 2.1; p = 0.007) and less injections (group 1: 3.6 ± 2.7, group 2: 6.1 ± 2.7; p < 0.001).
Conclusion A greater visual gain, in response to more intensive treatment during the first year, was maintained for at least 5 years in group 2 subjects. Our data confirm that in a real-world setting, early intensive treatment results in satisfying long-term visual outcomes.

Key messages

- In this best-practice study with a follow up of up to ten years, a sustained functional gain was achieved in DME with anti-VEGF treatment over many years in the real world.

- The absence of an underlying progressive, degenerative process, such as AMD, supports a favourable long-term prognosis whereas systemic comorbidity resulted in loss to follow-up and death in a remarkable proportion of our patients.

- More intensive early treatment, including a loading phase, may further contribute to a favourable long-term outcome in this, until recently, blinding disease.
Introduction

Diabetic macular oedema (DME) is the most common cause of severe vision loss in people aged 20–70 years and the second most common cause of visual impairment [1, 2]. Until the early twenty-first century, 11% of diabetic patients in Western Europe presented with eye disease and 0.3% eventually became blind [1, 3]. Since then, the potential of anti-VEGF drugs to prevent major vision loss and restore reading and driving vision in the majority of patients with diabetic maculopathy has been demonstrated, if the drugs are administered promptly [4].

Diabetic macular oedema (DME) is the most common cause of severe vision loss in people aged 20–70 years and the second most common cause of visual impairment [1, 2]. Until the early twenty-first century, 11% of diabetic patients in Western Europe presented with eye disease and 0.3% eventually became blind [1, 3]. Since then, the potential of anti-VEGF drugs to prevent major vision loss and restore reading and driving vision in the majority of patients with diabetic maculopathy has been demonstrated, if the drugs are administered promptly [4].

Recent evidence indicates that the outcomes from real-world studies are significantly poorer than those from controlled, prospective trials [15–19]. This may be linked to the absence of patient selection criteria, for example, pre-existing structural damage to the macula, and adherence to treatment in real-world settings [16, 20]. The majority of real-world studies in DME provide follow-up of only 2–3 years and a potential bias associated with availability of anti-VEGF drugs to patients. In Switzerland, the intensity of treatment for DME is not limited by the health insurance system. We therefore aimed to assess the long-term real-world treatment outcomes in patients with DME since the introduction of anti-VEGF therapy at our institution, making use of all available therapies and therapy combinations applied according to a best clinical practice pattern.

Patients and methods

In this single-centre, retrospective, consecutive case series, we included treatment-naïve patients with type 1 and type 2 diabetes mellitus who had received IVT for symptomatic, centre-involving DME at the Berner Augenklinik am Lindenhaus hospital in Bern, Switzerland.

Inclusion criteria were as follows: [1–4] a minimum follow-up of 2 years at our institution after the first intravitreal therapy.

The presence of any other macular disease (e.g. age-related macular degeneration (AMD) or retinal vascular disease of other origin that could interfere with the clinical outcome, proliferative diabetic retinopathy or absence of centre-involving maculopathy without vision loss), treatment of DME with intravitreal corticosteroid therapy only or as a first-line therapy or non-compliance with the suggested treatment resulted in exclusion from the analysis.

Patients were grouped depending on the date of first injection (between 2007 and 2012 for group 1 and between 2013 and 2017 for group 2). This grouping was based on a change in treatment approach at our institution by the end of 2012 from a minimally needed or pro re nata (PRN) therapy to more sustained therapy aimed at stabilising the early visual gains. This change was possibly based on the cost coverage of intravitreal therapy in DME by health insurance companies since late 2012. Group 2 resembles the current practice pattern following a treat and extend protocol, but not with a fixed loading phase of 5 monthly injections, whereas the difference in outcomes compared to group 1 would reflect the impact of medical learning and health cost coverage.

According to the institutional protocol, monthly anti-VEGF injections (either ranibizumab or aflibercept, but since 2012 due to cost coverage problems not bevacizumab) were performed until a significant reduction of intraretinal fluid was achieved, thereafter on an as needed basis (PRN strategy) under monthly to two-monthly visits. Retreatment was guided by anatomic criteria using SD-OCT aiming at functional and morphological stability until 2015. Since then, treatment strategy followed a treat and extend protocol with extension of visits and treatment intervals by 2 weeks until maximally 14 weeks if no new or recurrent fluid was present in OCT. A treatment interruption was offered in the absence of intraretinal fluid over more than 6 months. During therapy pausing, eyes were followed up minimally every 8 weeks according to patient availability.

The study was approved by the Institutional Ethics Committee, University of Bern (reference KEK 2017–00,143) and was carried out in accordance with the Declaration of Helsinki for medical research involving human subjects. Informed consent was obtained from all participants for use of their coded data.

Loss to follow-up was defined as non-compliance with the proposed treatment and/or missing clinic visits for more than 6 months for any reason (treatment futile, patient wishes, change of treating physician, illness or death). The end of follow-up and end of active treatment were defined as the date of the last clinic visit. The follow-up interval was the time from first injection to the last clinic visit.
Data acquisition

Patient data were retrieved from their electronic records and optical coherence tomography (OCT) database entries linked to patient corresponding visits. Data collected included Snellen’s BCVA, which was converted to the corresponding ETDRS letter scores (study with 85 letters representing a Snellen BCVA of 1.0 and 4 letters representing a BCVA of 0.02), intraocular pressure (IOP) and functionally relevant anatomical findings.

Central foveal thickness (CFT) was measured using a horizontal line algorithm with a length of 6 mm (Spectralis™, Heidelberg Instruments, Heidelberg, Germany). CFT was measured manually from the inner retinal surface to Bruch’s membrane on a micrometre scale.

Data were collected from the time of diagnosis until the last clinical examination before the study data lock on 20 July 2019. This resulted in a maximum of 13 junctures for measurement, including at the time of diagnosis, 1, 6 and 12 months after diagnosis, and annually thereafter, up to a maximum of 10 years. Comparisons between the groups were limited to 6 years of follow-up. Due to the retrospective nature of this study, we accepted a time window of 15% for the coincidence of the clinic visits with the study time junctures. The multiple imputation technique was applied for missing data only in patients still under follow-up at the time of study end [21].

This study was approved by the Institutional Ethics Committee, University of Bern (reference number: 330/14). All patients gave informed consent for the use of their data prior to inclusion in the study, strictly adhering to the tenets of the Declaration of Helsinki.

Statistical analyses

A series of non-parametric tests were conducted since data were not normally distributed. To compare the temporal profiles of BCVA and central retinal thickness (CRT) between the groups, the Mann–Whitney U test was performed. To compare nominal scaled data, the $X^2$ test was used. Multiple imputation was performed to estimate missing values in group 2 (since many of the patients had not yet reached 5 or 6 years of follow-up). Only the missing data from patients in group 2 still under therapy were imputed. Multiple imputation, as proposed by Rubin in 1978 [22], is a Monte Carlo method of handling data missing at random.

It was assumed that any systematic difference between the missing and observed values could be explained by differences in observed data. Multiple imputations are simulated draws from the posterior distribution of missing data. Furthermore, a complete case analysis was also conducted and compared to the findings of the imputed data. The complete case analysis was based only on those individuals without missing data. As Carpenter and Kenward proposed in 2008, it is helpful to present this analysis alongside the analysis performed on the partially observed data to evaluate how the conclusions differ [23]. All statistical analyses were performed using the SPSS software package V.23 (SPSS, Inc., Chicago, IL, USA). A $p$ value $< 0.05$ was considered statistically significant. Unless otherwise stated, the data are presented as mean values and standard deviations (SD).

Results

Of 217 treatment-naïve eyes (191 patients) that received anti-VEGF therapy for centre-involving DME, 66 eyes were excluded from the study (42 treated with corticosteroids as a first-line therapy, 17 had less than 1 year of follow-up, 6 underwent less than 3 injections and one patient was also affected by AMD). Therefore, 151 eyes were eligible for the present study.

Of these included 151 eyes, 63 (41.7%) received their first injection between 2007 and 2012 (group 1) and 88 (58.3%) were treated thereafter (group 2). The groups were similar in terms of mean age at inclusion (group 1: 64.3 ± 13.4 [29.9–90.7] years, group 2: 63.7 ± 13.7 [26.1–92.5] years; $p = 0.91$) and gender (42.9% versus 31.8% female respectively, $X^2$ test $p = 0.18$). The mean follow-up time differed as per protocol (group 1: 7.9 ± 3.1 [1.9–13.4] years, group 2: 4.1 ± 1.4 [1.8–7.2] years; $p = 1.38e-13$). In group 1, 82.5% were still under therapy after 5 years compared to 70.5% in group 2 ($p = 0.12$). Reasons for loss to follow-up are displayed in Table 1.

The pooled group achieved a gain of $+7.8 ± 13.4$ (−30 to +61) letters after 1 month, which was widely maintained by the end of the second year. After 2 years of follow-up, the letter gain was $+6.7 ± 14.0$ (−30 to +70) ETDRS letters, which decreased to $+4.5 ± 17.1$ (−49 to +73) ETDRS letters after 3 years and remained stable until 5 years of follow-up ($+4.0 ± 16.9$ [−38 to +74]) (Fig. 1a). Baseline mean BCVA was similar between the groups ($p = 0.29$).

![Table 1](https://example.com/table1.png)

|                  | First injection | n (% of all eyes) | Back to private ophthalmologist | Deceased | Severe systemic disease | Change of home address | Unknown reason |
|------------------|----------------|-------------------|-------------------------------|-----------|------------------------|------------------------|---------------|
| Group 1          | 2007–2012      | 11 (17.5%)        | 45.4%                         | 18.2%     | 18.2%                  | -                      | 18.2%         |
| Group 2          | 2013–2017      | 26 (29.5%)        | 69.3%                         | 11.5%     | 7.7%                   | 7.7%                   | 3.8%          |

* Springer
Fig. 1  

a. Evolution of best-corrected visual acuity (BCVA) over time (in ETDRS letters with 85 letters representing a BCVA of 1.0; mean ± standard error (SE)) in the full cohort. The distinctive loss in BCVA after 7 years of follow-up is likely related to an inherent selection bias. All patients not further systematically requiring treatment were referred back to their private ophthalmologists until DME recurrence.

b. Evolution of best-corrected visual acuity (BCVA) over time (in ETDRS letters; mean ± standard error (SE)) in two groups representing the periods from 2007 to 2012 and from 2013 to 2017.
(Fig. 1b). The visual gain 1 month after the first injection was similar between the groups (group 1: + 8.4 ± 15.1 [−23 to +60] letters, group 2: + 7.4 ± 12.3 [−30 to +61] letters; \(p = 0.99\)). This gain, however, was not maintained in group 1. The letter gain compared to baseline declined to + 5.3 ± 15.5 (−30 to +68) letters by the end of the second year, further to + 4.4 ± 15.0 (−30 to +70) letters by the second year and finally to + 2.4 ± 18.0 (−38 to +75) by year 5. On the other hand, the visual gain in group 2 increased to + 7.3 ± 12.2 (−15 to +63) letters by the end of the first year of therapy (\(p = 0.44\)) and to + 8.3 ± 13.0 (−30 to +53) letters by the end of the second year. In group 2, vision remained stable thereafter until 5 years of follow-up (+ 6.6 ± 14.8 [−23 to +60] letters) (Fig. 1b). After 1 year, 12.7% of eyes experienced a ≥ five-letter loss. Of the 82 eyes still under our follow-up after 5 years, 20 (24.4%) had lost ≥ five letters. In terms of BCVA, the groups differed over up to 3 years, but the difference in letter gains was significant only at year 2 (\(p = 0.038\)) (Fig. 1b). The differences among the two groups regarding visual acuity were confirmed for years 2 and 3, whether the missing data were imputed or not. Compared to group 2, more patients who started their therapy between 2007 and 2012 experienced a vision loss of ≥ five letters (year 1: 19.4% versus 8.0% \(p = 0.048\), year 4: 32% versus 8.7% \(p = 0.006\)).

Stratification of visual acuity improvement was performed according to baseline visual acuity (baseline BCVA ≤ 0.5, > 0.5; 70 ETDRS letters) and number of injections in the first year. Patients with a baseline BCVA up to 70 letters demonstrated a stronger visual improvement at all time points (visual gain +6.2 to +9.1 letters [baseline visual acuity ≤ 0.5] versus −2.3 to +1.7 letters [baseline BCVA > 0.5]) for each year (\(p < 0.001;\) Table 2). When excluding eyes that had received intravitreal corticosteroids and stratifying the remaining ones by number of injections in the first year (1–4 injections compared to five or more injections), eyes with five or more injections in the first year had only a slightly more pronounced improvement in visual acuity (reaching significance only after 2 years).

In contrast to visual acuity, CRT responded well to treatment and stabilised at around 300 (120–889) µm in the overall group between 3 and 10 years of follow-up (Fig. 2a). CRT at baseline was less in group 2 eyes (group 1: 564.6 ± 196.6 [241.7–1045.8] µm, group 2: 465.0 ± 136.2 [224–799] µm; \(p = 0.002\)) and, most probably related to earlier referral, remained less in group 2 over the following years (Fig. 2b). The imputation of missing data confirmed the differences between the two groups. In line with the PRN protocol in use, a dry macula (absence of any intraretinal fluid) was registered in 18.6% and 18.2% of eyes in group 1 and 2, respectively, after 12 months (\(p = 1.0\)), as displayed in Table 3.

All group 1 eyes received ranibizumab as first-line therapy. From 2014, treatment in 11 of 63 eyes was switched to aflibercept, while ranibizumab treatment was continued in 52 eyes. Treatment in group 2 eyes commenced with ranibizumab (n = 45) or aflibercept (n = 41). In the pooled group, 47 patients (31.1%) also received up to three bevazumab injections in this series (group 1: 39 patients, group 2: eight patients) before reimbursement of ranibizumab for the treatment of DME in Switzerland was instituted.

Group 1 patients received on average 3.6 ± 2.7 [1–13] injections in the first year, while group 2 patients received 6.1 ± 2.7 [1–12] injections during the same time period (\(p = 2.11\cdot e-08\)). This goes along with a higher number of examinations in group 2 in the first year (group 1: 6.6 ± 3.3 [1–17] examinations, group 2: 7.5 ± 2.1 [4–12] examinations; \(p = 0.007\)). The number of examinations and injections decreased during follow-up (Table 3). Differences between the groups may partially be explained by the use of corticosteroids, namely in the period of time before 2012. In group 1, more than half of the patients had at least one treatment with steroids (group 1: 40 (63.5%), group 2: 27 (30.7%); \(p < 0.0001;\) Table 4). In the full cohort, patients who had at least one steroid injection during the first year had a lower baseline visual acuity, whereas there was no difference in visual gain after 1 year.

**Discussion**

Since the first days of anti-VEGF use in clinical routine, patients enjoyed a relevant visual gain. This explains the high patient adherence over time in clinical practice, which adds to the strengths of our study. A relevant time effect between the two treatment periods may reflect an increasing confidence with the use of intravitreal therapy in DME and a change in the reimbursement pattern with full cost coverage since late 2012 in Switzerland. Best practice has changed in this period. The use of corticosteroids, which are cost-effective but prone to side effects, has declined compared to

| Table 2 Change in visual acuity (VA) over time, stratified by baseline VA |
|------------------|------------------|------------------|------------------|------------------|------------------|
|                  | \(n\) (baseline) | 1 year           | 2 years          | 3 years          | 4 years          | 5 years          |
| BCVA ≤ 0.5       | 104             | + 9.1            | + 8.9            | + 6.2            | + 6.4            | + 6.6            |
| BCVA > 0.5       | 47              | + 0.60           | + 1.7            | + 0.9            | - 1.5            | - 2.3            |
| Comparison (Mann–Whitney U test) | \(p = 2.92\cdot e-06\) | \(p = 3e-04\)   | \(p = 0.024\)   | \(p = 0.015\)   | \(p = 0.02\)   |
| 95% confidence interval | 4.85–10.21     | 3.04–9.86        | 0.34–9.84        | 1.63–12.15       | 1.29–13.11       |

BCVA best-corrected visual acuity
a more intensive use of on-label anti-VEGF drugs. Increasing knowledge of treatment options resulted in earlier referral of patients, as indicated by a lower retinal thickness at treatment initiation in the second period. In contrast, the impact of an intensified early treatment during the first year on visual gains [8, 24, 25] and improved diabetic retinopathy severity scores (DRSS) with anti-VEGF drugs had not been demonstrated until late 2013 [13, 14] and thus, may have had less impact. A decline in treatment demand over time in our patients is in accordance with published evidence [9, 12]. In a prospective clinical study setting, patients not able or willing to attend regular monthly visits during the first year of treatment would not likely be included in the study. In a real-world setting, young patients in their working lives will seek assistance in order to maintain their daily working activities, but cannot afford frequent visits due to the risk to their employment. These points may at least partially explain the less favourable outcomes in this real-world setting compared to clinical trials. In comparison, the lower adherence to treatment in the second period in our institution reflects an increasing trend to seek anti-VEGF treatment and follow-up by the patients’ family ophthalmologists, rather than a treatment interruption (Table 1) [26]. A more restricted use of triamcinolone and focal and pan-retinal laser photocoagulation and their inherent side effects on visual performance may have added to reduce the treatment burden and patient fears, and thus, have added to the treatment adherence in real-world settings. In addition, patients may also have gathered confidence that their disease, until recently blinding [1, 2, 27, 28], was well treatable in a vast majority of instances with this therapy [8].

Early in the era of anti-VEGF treatment, we aimed to prevent blinding and to preserve some vision in DME in the long term and applied all available therapeutic options to achieve this. Corticosteroids were widely used based on the low cost of off-label triamcinolone compared to ranibizumab (registered for several years for AMD), but neither were approved nor reimbursed for DME. Consistently, the visual gain achieved after the first injection and by end of the first year was not maintained in group 1 compared to group 2. Moreover, 28% of group 1 patients experienced a significant vision loss (> 15 letters) during the first year, which was not linked to cataract development, compared to 8% in eyes treated since 2013. The functional evolution was partially paralleled by morphological parameters, evidenced by a reduced CRT in the second period than the first (Fig. 2b). A patient retention rate of 70–80% over 5 years in both groups adds to the 1-year findings of two prospective studies on high patient satisfaction [29, 30].

One prospective, randomised, interventional, multicentre clinical trial showed that the visual improvement achieved over 6 months in DME patients treated with ranibizumab, with or without additional laser therapy, could be stabilised for up to 2 years of follow-up [25]. Those who were treated with ranibizumab monotherapy gained +7.2 letters within the first 6 months, compared to 6.7 letters in our study with a significantly lower number of injections. This letter gain was maintained in the prospective setting, as in our real-world study, over 2 years and remained stable at between +6.6 and 7.7 letters [25]. The remarkable difference in the number of injections between the prospective study with monthly injections, compared to a total of 7.8 injections over 2 years in our patients, is comparable to the RESTORE study findings [10]. The difference in the number of injections and visual gain between our two groups of eyes indicates that a follow-up of 2 years must not be predictive of long-term functional stability. Patients in the second period treated more intensely in the first year maintained their visual gain for up to 5 or more years, whereas undertreatment may explain the progressive vision loss in the first group (Fig. 1b, Table 3). This is well in line with treatment experience in other retinovascular disorders, i.e. retinal vein occlusion [31, 32].

Our real-life study confirms that visual acuity can be maintained for at least 5 years without any central laser treatment if patients are systematically treated with anti-VEGF agents, as long as retinal fluid is present. The assumption that laser therapy might reduce the number of anti-VEGF injections and DME severity [28] has not been confirmed [10, 33–35].

Our data show a remarkable decline in the number of patients still requiring active treatment over a 5-year period, which was also observed in the extension of the RISE and RIDE studies [36]. This suggests that anti-VEGF treatment for DME induces vascular wall stabilisation, which benefits the eye far beyond the direct treatment effect, although over a probable limited period of time. This differentiates DME from the chronically progressive and destructive process of neovascular AMD [18, 19].

One limitation of our study is the low number of eyes that were still under our treatment after 7 years. This is the result of our institutional treatment standard proposing a referral of patients back to their family ophthalmologists after reaching visual stability. Most patients lost to follow-up had been sent back to their family ophthalmologists due to visual stability (45.5% in group 1, 69.2% in group 2; \( p = 0.12 \)). A portion of 45–69% of patients achieving functional stability, on the other hand, underlines the importance of anti-VEGF therapy on long-term stabilisation of retinal function. Since we have no information about the fate of eyes after referral back to
family ophthalmologists, our results are probably not representative beyond this time point. Last observation carried forward (LOCF) is an imputation technique used in prospective clinical studies to carry the last assessed value forward to visits where a value is missing. Owing to the retrospective character and less rigid selection criteria, we preferred not to apply this technique to patients in this study whose treatment was suspended. Consequently, a selection bias towards the “more complex” patients with a persisting treatment demand due to chronic recurrent or refractory macular oedema and incomplete response to treatment may explain the vision loss after 6–7 years of treatment. Hence, this does not reflect our impression of the long-term outcome of anti-VEGF treatment in DME.

Long-term stabilisation appears feasible in the majority of DME patients in the real-world setting obviously to a higher degree than in exudative AMD, in which one-third of patients maintain a driving vision over 10 years [37]. This is important since patients with DME are significantly younger than those with AMD and frequently both eyes are affected. Moreover, in contrast to neovascular AMD, continuous treatment of DME eyes appears not to be necessary in a large portion of eyes.

### Conclusion

A sustained functional gain may be achieved in DME with anti-VEGF treatment over many years in the real world. The absence of an underlying progressive, degenerative process, such as AMD, supports a favourable long-term prognosis, whereas systemic comorbidity resulted in loss to follow-up and death in a remarkable proportion of our patients. More intensive early treatment, including a loading phase, may further contribute to a favourable long-term outcome in this, until recently, blinding disease.

### Acknowledgements

Editorial assistance, in the form of language editing and correction, was provided by Proof-Reading-Service.com.

### Author contribution

IZ substantially contributed to the acquisition and interpretation of the data and was a major contributor in writing the manuscript. IBP substantially contributed to the acquisition and analysis as well as interpretation of the data and was a major contributor in writing the manuscript. CG substantially contributed to the conception and design of the work, data acquisition and interpretation of the data and was a key contributor in writing the manuscript. All authors read and approved the final manuscript.

### Funding

Open Access funding provided by Universit"at Bern.

### Declarations

Conflict of interest JGG acts as advisor for several pharmaceutical companies and contributes to several clinical studies. The underlying manuscript is independent of these activities. The author did not re-

---

**Table 3** Percentage of eyes with residual intraretinal fluid within the macula, including only patients still under treatment. The $p$ values for group comparisons are annotated after the values of group 2. Significant group comparisons are highlighted in bold.

|                | Group 1: 2007–2012 |                | Group 2: 2013–2017 |
|----------------|--------------------|-----------------|--------------------|
| Residual intraretinal fluid (%) | Number of visits (mean ± SD) | Number of injections (mean ± SD) | Residual intraretinal fluid (%) | Number of visits (mean ± SD) | Number of injections (mean ± SD) |
| 1 year n=63  | 81.4 ± 3.3 | 3.6 ± 2.7 | n = 88 | 81.8 (p = 1.0) | 7.5 ± 2.1 (p = 0.007) | 6.1 ± 2.7 (p = 2.11e-08) |
| 2 years n=63 | 74.2 ± 3.3 | 1.6 ± 1.7 | n = 88 | 87.2 (p = 0.053) | 5.4 ± 2.3 (p = 0.13) | 3.4 ± 2.7 (p = 3.94e-05) |
| 3 years n=57 | 75.9 ± 3.0 | 1.8 ± 1.7 | n = 65 | 75.0 (p = 1.0) | 4.8 ± 2.1 (p = 0.77) | 2.9 ± 2.8 (p = 0.09) |
| 4 years n=57 | 70.8 ± 3.3 | 1.4 ± 1.9 | n = 52 | 76.1 (p = 0.64) | 4.5 ± 1.9 (p = 0.30) | 2.6 ± 2.7 (p = 0.039) |
| 5 years n=53 | 68.0 ± 3.4 | 1.6 ± 1.8 | n = 31 | 77.4 (p = 0.45) | 4.8 ± 2.1 (p = 0.86) | 3.6 ± 3.7 (p = 0.028) |

$p$ values for group comparisons are annotated after the values of group 2. Significant group comparisons are highlighted in bold. SD standard deviation.

**Table 4** Number of patients receiving intravitreal steroid injections in the first year and change in visual acuity (VA).

|                | n | Baseline VA mean ± SD | VA change after 1 year mean change ± SD |
|----------------|----|-----------------------|----------------------------------------|
| Steroids in the 1st year | 48 | 55.9 ± 15.2 | +7.5 ± 16.3 |
| No steroids in the 1st year | 103 | 65.1 ± 14.6 | +6.0 ± 12.3 |
| Mann–Whitney U test | p = 1.66e-06 | p = 0.34 |
| 95% confidence interval | 4.9 to 15.1 | −6.3 to 3.2 |
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Holekamp NM (2016) Overview of diabetic macular edema. Am J Manag Care. 22(10 Suppl):s284-s291.
2. Lee R, Wong TY, Sabaanyagam C (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2:17. https://doi.org/10.1186/s40662-015-0026-2
3. Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naiddoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study (2016) Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care 39(9):1643–1649. https://doi.org/10.2373/dc15-2171
4. Ip MS, Domalpally A, Hopkins JI, Wong P, Ehrlich JS (2012) Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130(9):1145–1152. https://doi.org/10.1001/archophthalmol.2012.1043
5. Jan S, Nazim M, Karim S, Hussain Z (2016) Intravitreal bevacizumab: Indications and complications. J Ayub Med Coll Abbottabad 28(2):364–368
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. https://doi.org/10.1056/NEJMoa054481
7. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33(11):2399–2405. https://doi.org/10.2337/dc10-0493
8. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A. RESTORE study group (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625. https://doi.org/10.1016/j.ophtha.2010.11.031
9. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801. https://doi.org/10.1016/j.ophtha.2011.12.039
10. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P, RESTORE Extension Study Group (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121(5):1045–1053. https://doi.org/10.1016/j.ophtha.2013.11.041
11. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soot Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123(11):2376–2385. https://doi.org/10.1016/j.ophtha.2016.07.032
12. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialist (EURETINA). Ophthalmologica 237(4):185–222. https://doi.org/10.1159/000458539
13. Wykoff CC, Eichenbaum DA, Roth DB, Hill L, Fung AE, Haskova Z (2018) Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy. Ophthalmol Retina 2(10):997–1009. https://doi.org/10.1016/j.oret.2018.06.005
14. Ip MS, Zhang J, Ehrlich JS (2017) The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology 124(5):596–603. https://doi.org/10.1016/j.ophtha.2017.01.003
15. Kodjikian L, Bellocq D, Mathis T (2018) Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int 2018:8289253. https://doi.org/10.1155/2018/8289253
16. Wilke RGH, Finger RP, Sachs HG (2017) Daten zur Behandlungsrealität des diabetischen Makulaödems mit Ranibizumab [Real-life data on the treatment of diabetic macular edema in Germany]. Klin Monbl Augenheilkd 234:1502–1507. https://doi.org/10.1055/s-0043-115901
17. Granström T, Forsman H, Lindholm Olinder A, Gkretsis D, Eriksson JW, Granstrom E, Leksel J (2016) Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. Diabetes Res Clin Pract 121:157–165. https://doi.org/10.1016/j.diabres.2016.09.015
18. Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wieden A, Wilhelm H, Ziemssen F (2016) Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health Qual Life Outcomes 14(1):132. https://doi.org/10.1186/s12955-016-0536-1
19. Wecker T, Ehlicken C, Bühler A, Lange C, Agostini H, Böhringer D, Stahl A (2017) Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101:353–359. https://doi.org/10.1136/bjophthal-2016-308668
20. Ehlicken C, Helms M, Böhringer D, Agostini HT, Stahl A (2017) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. ClinOphthalmol 12:13–20. https://doi.org/10.2147/OPTH.S151611
21. Yuan YC (2010) Multiple imputation for missing data: concepts and new development. SAS Institute Inc. Rockville 49:1–11
22. Rubin DB (1978) Multiple imputation in sample surveys—a phe-nomenological Bayesian approach to nonresponse. Proceedings of the Survey Research Methods Section of the. Am Stat Assoc 20–34
23. Carpenter JR, Kenward MG, (2008) Missing data in clinical trials—a practical guide. Birmingham: National Health Service Coordinating Centre for Research Methodology. http://www.pcpoh.
24. Joussen AM, Smyth N, Niessen C (2007) Pathophysiology of diabetic macular edema. Dev Ophthalmol 39:1–12. https://doi.org/10.1159/000098498.

25. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatet E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JJ, Elliott D, Campochiaro PA, READ-2 Study Group (2010) Two-year outcomes of the ranibizumab for edema of the macula in the ranibizumab in Hispanic and non-Hispanic Whites with diabetic macular edema. Dev Ophthalmol 39:1–12. https://doi.org/10.1159/000098498.

26. Turpcu A (2015) Visual impairment and blindness avoided with treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. Graefes Arch Clin Exp Ophthalmol 257(1):1405–1410. https://doi.org/10.1007/s00417-020-04667-y.

27. Varma R, Bressler NM, Doan QV, Danese M, Dolan CM, Lee A, Turpcu A (2015) Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic Whites with diabetic macular edema in the United States. Ophthalmology 122(5):982–989. https://doi.org/10.1016/j.ophtha.2014.12.007.

28. Romero-Aroca P (2013) Current status in diabetic macular edema treatments. World J Diabetes 4(5):165–169. https://doi.org/10.4239/wjd.v4.i5.165.

29. Garweg JG, Stefanickova J, Hoyo C, Schmelter T, Niesen T, Sowade O, Sivaprasad S, AQUA Investigators (2019) Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: the AQUA study. Ophthalmol Retina 3(7):567–575. https://doi.org/10.1016/j.ijeret.2019.03.012.

30. Mitchell P, Bressler N, Tolley K, Gallagher M, Petrollo J, Ferreira A, Wood R, Bandello F, RESTORE Study Group (2013) Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol 131(10):1339–1347. https://doi.org/10.1001/jamaophthalmol.2013.4592.

31. Light JG, Tian J, Wenick AS (2020) Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy: prognosis and predictive factors. Ophthalmol Retina 2(5):3046–3069. https://doi.org/10.1016/j.ijeret.2020.11.010.

32. Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, Creuzot-Garcher C, Spital G, Sakamoto T, Dunger-Baldauf C, McAllister IL, all the LUMINOUS study investigators (2020) Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global LUMINOUS study. PLoS One 15(6):e0234739. https://doi.org/10.1371/journal.pone.0234739.

33. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW, Diabetic Retinopathy Clinical Research Network (2015) Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122(2):375–381. https://doi.org/10.1016/j.ophtha.2014.08.047.

34. Bressler SB, Glassman AR, Almukhtar T, Bressler NM, Ferris FL, Googe JM Jr, Gupta SK, Jampol LM, Melia M, Wells JA 3rd, Diabetic Retinopathy Clinical Research Network (2016) Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol 164:57–68. https://doi.org/10.1016/j.ajo.2015.12.025.

35. Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, Bezlýak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J, RETAIN Study Group (2016) Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 100(6):787–95. https://doi.org/10.1136/bjophthalmol-2015-307249.

36. Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS, RIDE and RISE Research Group (2015) Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the Phase III RIDE and RISE Trials. Ophthalmology 122(12):2504–13.e1. https://doi.org/10.1016/j.ophtha.2015.08.006.

37. Garweg JG, Zirpel JJ, Gerhardt C, Pfister I (2018) Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun. Graefes Arch Clin Exp Ophthalmol 256(8):1553–1555. https://doi.org/10.1007/s00417-018-4005-x.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.